Desensitisation approaches effective against hayfever-like allergies

Dec 08, 2010

Immunotherapy given as pills or drops under the tongue is a safe and effective way to treat hayfever-like allergies caused by pollen and dust mites, according to a new Cochrane Systematic Review. The researchers say the approach is an attractive alternative to immunotherapy injections in children.

Common treatments for hayfever-like symptoms caused by allergies include antihistamines and nasal . If these prove unsuccessful, doctors may recommend immunotherapy, a desensitisation approach that involves exposing patients to increasing doses of an . Traditionally immunotherapy was carried out by injection, but allergens are now also applied as or drops under the tongue.

Although a 2003 Cochrane review suggested sublingual immunotherapy was effective, the findings were based on a relatively small number of trials. Much more evidence is now available and the researchers were able to add another 38 studies to their current review, totalling 60 altogether. They included trials of and dust mites, as well as one trial of cat allergens. Sublingual immunotherapy significantly reduced symptoms of allergic rhinitis and requirements for medication compared to placebos. The results confirm the treatment is effective and has very few serious adverse effects.

The larger number of trials allowed the researchers to make stronger recommendations for use of sublingual immunotherapy in children. "This is an attractive approach for treating allergies in children. It is a more convenient alternative compared to injection immunotherapy," said Suzana Radulovic, one of the review authors, who is currently based at the Paediatric Research Department at St Thomas' Hospital in London, UK. "It is encouraging to see similar treatment effects in children compared to those in adults."

Overall, treatment effects comparable to those seen in the previous review provide greater reassurance for clinical practitioners. "Sublingual immunotherapy is an effective treatment for . With the inclusion of larger, better designed trials, we can be much more confident about the results," said Radulovic. "What we'd like to see now is more work on optimum dosage and treatment times."

Explore further: US hunts contacts of seriously ill Ebola patient

add to favorites email to friend print save as pdf

Related Stories

Latest research on allergies: Specific immunotherapy can help

Jun 11, 2008

The German Institute for Quality and Efficiency in Health Care has assessed recent evidence on allergies. It found that the once controversial immune therapy against allergy symptoms can definitely help many people with allergies.

Researchers evaluating food allergy treatment

Apr 17, 2008

Researchers at National Jewish Medical and Research Center are conducting trials to evaluate a method to prevent allergic reactions to food. They are feeding peanut- and egg-allergic people increasing doses of an investigational ...

Recommended for you

US hunts contacts of seriously ill Ebola patient

1 hour ago

US health officials scoured the Dallas area Wednesday for people—including schoolchildren—who came in contact with a Liberian man who was diagnosed with Ebola, as it emerged a hospital mix-up saw him initially turned ...

Australia lifts Ebola donation to $16 million

1 hour ago

Australia more than doubled its donation to the fight against Ebola in West Africa to 18 million Australian dollars ($16 million) on Thursday, but resisted demands to send personnel.

UN says Syria vaccine deaths was an NGO 'mistake'

13 hours ago

The recent deaths of Syrian children after receiving measles vaccinations was the result of a "mistake" by a non-governmental partner who mixed in a muscle relaxant meant for anesthesia, a spokesman for the U.N. secretary-general ...

First US child dies from enterovirus D68

14 hours ago

A child in the northeastern US state of Rhode Island has become the first to die from an ongoing outbreak of a respiratory virus, enterovirus D68, health officials said Wednesday.

User comments : 0